| TRADING CENTER |
| Behind the Business: 3 Questions for Vical - MotleyFool.com | |
| Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial - GlobeNewswire | |
| Vical Added to NASDAQ Biotechnology Index - GlobeNewswire | |
| Semi-Annual Changes to the NASDAQ Biotechnology Index - GlobeNewswire | |
| Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases - GlobeNewswire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 56.48 | -0.37 / -0.65% | 10.80 |
| GILD | Gilead Sciences Inc | 46.62 | 0.03 / 0.06% | 18.00 |
| CELG | Celgene Corporation | 55.53 | -0.44 / -0.79% | 66.90 |
| 2008 Revenue: | $8.0 M | Headquarters: San Diego, CA |
| Employees: | 118 | CEO: Vijay B. Samant |
| Net Income: | $-36,896,000.0 | Industry: Biotechnology |
| Market Cap: | $149.2 M | Website: www.vical.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| VICL | 2.86 | -0.02 / -0.69% | 2.88 | 2.89 | 2.81 | Profile Chart News |